Ben Doranz, Ph.D.

Ben Doranz is President and CEO of Integral Molecular, whose mission is to create transformative technologies that advance the discovery of therapeutics against difficult protein targets. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company’s growth since its inception, bringing 6 different technologies from research to market. His scientific expertise focuses on viruses, membrane proteins, and antibodies. He is an inventor on 50 of the company’s filed patents and an author on over 100 publications, including articles published in Cell, Science, and Nature. Dr. Doranz earned his Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania and his MBA at Wharton.